Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Acquisitions & Divestments (2016 - 2026)

Gyre Therapeutics has reported Change in Acquisitions & Divestments over the past 12 years, most recently at $4.2 million for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments changed N/A to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $15.4 million for FY2025, N/A changed from the prior year.
  • Change in Acquisitions & Divestments was $4.2 million for Q4 2025 at Gyre Therapeutics, down from $11.2 million in the prior quarter.
  • Over five years, Change in Acquisitions & Divestments peaked at $27.6 million in Q1 2021 and troughed at $2.5 million in Q1 2022.
  • The 3-year median for Change in Acquisitions & Divestments is $7.5 million (2021), against an average of $9.6 million.
  • The largest YoY upside for Change in Acquisitions & Divestments was 17.56% in 2021 against a maximum downside of 91.44% in 2021.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $2.9 million in 2021, then dropped by 12.63% to $2.5 million in 2022, then skyrocketed by 69.29% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Acquisitions & Divestments are $4.2 million (Q4 2025), $11.2 million (Q1 2025), and $2.5 million (Q1 2022).